Q3: 2025-11-06 Earnings Summary
EPS of -$0.16 misses by $0.08
| Revenue of $87.31M (69.10% Y/Y) beats by $10.11M
Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health November 11, 2025 2:00 PM EST
Company Participants
Sheldon Koenig - President, CEO & Director LeAnne Bloedon
Conference Call Participants
Dharmesh Patel Fatima Rodriguez Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Jason Zemansky - BofA Securities, Research Division Rick Miller -…
Q3: 2025-11-06 Earnings Summary
EPS of -$0.16 misses by $0.08
| Revenue of $87.31M (69.10% Y/Y) beats by $10.11M
Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health November 11, 2025 2:00 PM EST
Company Participants
Sheldon Koenig - President, CEO & Director LeAnne Bloedon
Conference Call Participants
Dharmesh Patel Fatima Rodriguez Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Jason Zemansky - BofA Securities, Research Division Rick Miller - Cantor Fitzgerald & Co., Research Division
Presentation
Operator
Good day, everyone. My name is Leila, and I will be your conference operator today. At this time, I would like to welcome you to Esperion’s key opinion leader Investor event, Breaking the Statin Intolerance Barrier, Closing the Care Gap in Cardiovascular Health. [Operator Instructions] At this time, I would like to turn the call over to Sheldon Koenig, President and CEO for Esperion.
Sheldon Koenig President, CEO & Director
Thank you so much. Good afternoon, everyone, and thank you for joining us for this most important segment on Statin Intolerance Barrier, Closing the Care Gap in Cardiovascular Health. If we can go to the next slide, please. So our forward-looking statement and disclosures. I won’t read it, but it will be available on our IR site.
Next slide. So this is our agenda today. First of all, I just want to thank our speakers who have joined us today, Dr. Fatima Rodriguez, who – all of our speakers will be introducing themselves in the later half of this session. Dr. Dharmesh Patel; and LeAnne Bloedon, our Vice President, Head of Development, who will also be giving a presentation post my remarks.
Our agenda today, opening and introduction. The next segment will be when treatment becomes a barrier, empowering patients to stay on therapy and then a question-and-answer session with both Dr. Fatima Rodriguez and Dr. Dharmesh Patel. And again, we thank